Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:05 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 337 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Parent Child Relationship Clear all

Conditions: Down Syndrome, Intellectual Disability, Sexuality, Parent-Child Relations
Interventions: Parent training; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: Not listed
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Park Ridge, Illinois

Conditions: Melanoma (Skin)
Interventions: gp100 antigen, incomplete Freund's adjuvant, sargramostim, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 2
States / cities: Los Angeles, California • Ann Arbor, Michigan

Conditions: Yellow Fever, Yellow Fever Immunisation
Interventions: ISA-720, MVA Smallpox Vaccine, MVA-BN Yellow Fever Vaccine, Placebo, YF Vax 17D Strain; Drug · Biological · Other
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 2
States / cities: Iowa City, Iowa • St Louis, Missouri

Conditions: Hunger, Satiety
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Myelodysplastic Syndromes
Interventions: PR1 leukemia peptide vaccine, incomplete Freund's adjuvant, sargramostim; Biological
Lead sponsor: The Vaccine Company; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2007
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Prostate Cancer, Erectile Dysfunction
Interventions: sildenafil citrate and questionaires, placebo tablets and questionaires; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Male only
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2014
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, progenipoietin, tyrosinase peptide; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 2
States / cities: Los Angeles, California

Conditions: Diabetes Mellitus, Type 2
Interventions: IcoSema, Semaglutide 1 mg; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 76
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 65 more

Conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer, EGFR Overexpression, Metastatic Esophageal Carcinoma, HER-2 Positive Esophageal Cancer
Interventions: Combination of MVF-HER-2 (597-626) and MVF-HER-2 (266-296) emulsified with ISA 51; Biological
Lead sponsor: Pravin T.P Kaumaya; Other
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Indianpolis, Indiana

Conditions: Bipolar Disorder, Depression
Interventions: Interpersonal psychotherapy for prevention with adolescents, Educational clinical monitoring; Behavioral
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 12 Years to 17 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Intraocular Melanoma, Melanoma (Skin)
Interventions: MART-1 antigen, gp100 antigen, incomplete Freund's adjuvant, recombinant interleukin-12, sargramostim, tyrosinase peptide, alum adjuvant, adjuvant therapy; Biological · Drug · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2007
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension, Diabetes, Dyslipidemia
Interventions: Medication Adherence Smartphone App; Other
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 3
States / cities: Little Rock, Arkansas

Conditions: Neck Pain, Low Back Pain
Interventions: Muscle Pattern Recognition (MPR); Device
Lead sponsor: iTech Medical, Inc.; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 480 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 3
States / cities: Irvine, California • Portage, Michigan • Salt Lake City, Utah

Conditions: Premature Infants, Parent-Child Relations
Interventions: H-HOPE Intervention; Behavioral
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: Not listed
Enrollment: 1,882 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Chicago, Illinois • Park Ridge, Illinois • Durham, North Carolina + 1 more

Conditions: Herpes Genitalis
Interventions: Valaciclovir, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 384 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 58
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 50 more

Conditions: Parenting, Parent-Child Relations
Interventions: Not listed
Lead sponsor: Child Development Resources; Other
Eligibility: Not listed
Enrollment: 350 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Williamsburg, Virginia

Conditions: Post-Ischemic Stroke
Interventions: Placebo, dalfampridine-ER 7.5mg, dalfampridine-ER 10mg; Drug
Lead sponsor: Acorda Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 377 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 70
States / cities: Gilbert, Arizona • Berkeley, California • Long Beach, California + 61 more

Conditions: Female Stress Urinary Incontinence Due to Intrinsic Sphincter Deficiency
Interventions: Coaptite®; Device
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 459 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 20
States / cities: Wetumpka, Alabama • Surprise, Arizona • Encinitas, California + 17 more

Conditions: Pelvic Floor Muscle Weakness, Pelvic Floor Disorder, Pelvic Pain, Hip Strength
Interventions: Not listed
Lead sponsor: George Fox University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newberg, Oregon

Conditions: Preterm, Parent-Child Relations, Parents, Development, Infant, Sensory Integration Dysfunction
Interventions: SENSE multisensory program, Monitored standard of care; Behavioral
Lead sponsor: University of Southern California; Other
Eligibility: 1 Day to 7 Days
Enrollment: 215 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Melanoma
Interventions: MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine; Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC)
Interventions: Sigvotatug Vedotin, Pembrolizumab; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 714 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 85
States / cities: Fairbanks, Alaska • Fullerton, California • Golden, Colorado + 57 more

Conditions: PTSD, Depression, Parent-Child Relations
Interventions: Parenting-STAIR Modular (PSTAIR-M); Behavioral
Lead sponsor: New York University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 3
States / cities: El Paso, Texas • Killeen, Texas • San Antonio, Texas

Conditions: Depression, Information Dissemination, Social Determinants of Health
Interventions: Quality Improvement Program, Resources for Services Expert Team, Community Engagement and Planning Council; Other · Behavioral
Lead sponsor: RAND; Other
Eligibility: 18 Years and older
Enrollment: 1,246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 1
States / cities: Gardena, California

Search by objective public record fields.

Parents as the Primary Sexuality Educators for Their Young Adults With Down Syndrome

Vaccine Therapy in Treating Patients With Stage II Melanoma That Can Be Removed by Surgery

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Which is a Better Breakfast? Egg or Cereal?

Vaccine Therapy and GM-CSF in Treating Patients With Low-Risk or Intermediate-Risk Myelodysplastic Syndrome

Study of Sildenafil Citrate During and After Radiotherapy/Hormone Therapy for Erectile Function Versus Radiotherapy/Hormone Therapy for Prostate Cancer

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Semaglutide (COMBINE 2)

HER-2 B Cell Peptide Vaccine

Early Detection and Prevention of Mood Disorders in Children of Parents With Bipolar Disorder

Vaccine Therapy and Interleukin-12 With Either Alum or Sargramostim After Surgery in Treating Patients With Melanoma

Is a Smartphone Application Effective as an Oral Medication Adherence Aid

Study to Demonstrate That Muscle Pattern Recognition (MPR) is an Effective Evaluation Tool for Musculoskeletal Neck or Back Pain

Implementation of an Evidence Based Parentally Administered Intervention for Preterm Infants

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.

CDR Investing in Fatherhood Process Study & Evaluation

A Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets.

This is a Post Approval Study of Coaptite® in the Treatment of Female Urinary Incontinence

Does Hip Strength Impact Active Females Rate of Pelvic Floor Dysfunction? The Primary Goal of This Research is to Collect Data on Hip Strength for Active Females and Assess if There is a Relationship Between Hip Strength and Pelvic Floor Dysfunction (PFD).

Sensory Optimization of the Hospital Environment

Novel Adjuvants for Peptide-Based Melanoma Vaccines

This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.

Parenting STAIR: Adapting a Trauma-Focused Parenting Intervention for Military-Connected Mothers and Their Children

Community Partners in Care is a Research Project Funded by the National Institutes of Health